PRESS RELEASE At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme’s Lemtrada in Pivotal Studies - In approximately 70 percent of patients, disability scores improved or - Alemtuzumab - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2014-10-09 14:57:39 Immunology Biology Autoimmune diseases Alemtuzumab Genzyme Interferon beta-1a Interferon Therapies under investigation for multiple sclerosis Treatment of multiple sclerosis Multiple sclerosis Cytokines Immune system		PRESS RELEASE At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme’s Lemtrada in Pivotal Studies - In approximately 70 percent of patients, disability scores improved or Add to Reading List Source URL: en.sanofi.com Download Document from Source Website File Size: 94,94 KB Share Document on Facebook

	PDF Document DocID: 1rhTx - View Document
	Blue Cross Blue Shield of Wyoming Prime Therapeutics Specialty Pharmacy Drug Management List Definition of specialty medications: Specialty medications are generally prescribed for people with complex or ongoing medical DocID: 1r7Ye - View Document
	Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio DocID: 1qn6Z - View Document
	PDF Document DocID: 1ptj0 - View Document
	MOUNTAIN VIEW PHARMACEUTICALS DocID: 1oFr0 - View Document